Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting ...

The GBS | CIDP Foundation International has unveiled survey data that paints a sobering picture of the physical, social, and financial challenges faced by individuals with Guillain-Barré Syndrome ...

Senators Thom Tillis (R-NC) and Mark Kelly (D-AZ) introduced the bipartisan Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act, legislation to ensure individuals with rare ...

“We have seen patients where they don’t know what the trigger was, but most often you typically hear about the preceding infection of some kind,” said Donna Hartlem, the executive director of GBS/CIDP ...